Non Small Cell Lung Cancer Clinical Trial
Official title:
A Multicenter Phase 2 Study Comparing 99m Tc EC-DG SPECT/CT With 18F FDG PET/CT in the Evaluation of Patients With Non-small Cell Lung Cancer (NSCLC)
Verified date | March 2013 |
Source | Cell>Point LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a multiple-center Phase 2 study designed to expand the patient safety and clinical information using 99m Tc-Ec-DG with Spect/CT imaging, to develop procedures and methods for evaluation of the imaging studies, to determine comparability of diagnostic information between SPECT and SPECT/CT imaging and to to compare the safety and efficacy of 99m Tc-EC-DG SPECT/CT with 18F-FDG PET/CT in imaging patients with biopsy confirmed diagnosis of Non-small Cell Lung Cancer.
Status | Completed |
Enrollment | 22 |
Est. completion date | December 2010 |
Est. primary completion date | July 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female patients at least 18 years old; - Have non-incisional biopsy demonstrating definitive evidence for NSCLC (Cytology results confirming NSCLC from a bronchoscope procedure will also be acceptable) and have not been treated for lung cancer (surgery, radiation and/or chemotherapy); A copy of the actual report must be requested by the patient through a medical release form if not already done. The copy must be available to the study doctor within 28 days of the screening visit/ Visit 1 ; - Be certified as per centers for Medicare and Medicaid Services (CMS) requirements and be eligible for a PET scan; - Have an Eastern Co-operative Oncology Group (ECOG) performance rating = 2 (see Appendix 1); - Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy); - Females of childbearing potential and males with female sexual partners of childbearing potential must agree to use one of the following acceptable birth control methods: 1. Surgically sterile (hysterectomy or bilateral oophorectomy); 2. Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to study initiation). Documentation is required; 3. Intrauterine device (IUD) in place for at least 3 months; 4. Double-barrier method (condom and diaphragm) with spermicide for at least 14 days prior to screening and through study completion; 5. Stable hormonal contraceptive (oral, topical, vaginal or implanted/injected) for at least 3 months prior to study and through study completion; 6. Abstinence; 7. Single-barrier method for at least 14 days prior to screening and though study completion for vasectomized males or females with vasectomized partners; - Have a fasting blood glucose of less than 200 mg/dL at screening; - Have reported clinical symptoms consistent with a confirmed diagnosis of NSCLC; - BE able to tolerate SPECT/CT and PET/CT imaging. This includes: - Laying in the same position without moving for approximately 45 minutes; - Able to tolerate a claustrophobic area; - Ability to hold their arms overhead for approximately 45 minutes; - Be able to fast prior to SPECT/CT and PET/CT imaging, with length of fasting dependent on the time of the scan (or follow site specific fasting and/or diet restrictions): - A morning scan (08:00-12:00) will require fasting from midnight; - An afternoon scan (12:00-onward) will require a minimum 6 hour fast; - Be able to eat a high protein/low carbohydrate meal as the last meal before SPECT/CT and PET/CT imaging (or follow site specific fasting and/or diet restrictions); - Be able to make the scheduled appointments within the designated time windows (PET/CT imaging within 7 days of qualifying for the study, the second imaging session with SPECT/CT imaging 1 - 3 days after the initial imaging visit, with at least 24 hours between PET/CT and SPECT/CT imaging). If the PET/CT was done as part of the pre-screening procedures and was conducted on a previously qualified PET camera for the study, the SPECT/CT must be done within 45 days of the PET/CT imaging procedures; - Have safety laboratory values that in the opinion of the Investigator do not place the patient at undue risk if the patient were to participate in the study. This includes (but is not limited to): - Alanine aminotransferase 2.5 × upper limit of normal (ULN); - Aspartate aminotransferase 2.5 × ULN; - Creatinine 2.5 × ULN; - Bilirubin 2.0 × ULN; - Able to understand and provide signed informed consent; - Females of childbearing potential must have a negative urine or serum ß-human chorionic gonadotropin (hCG) pregnancy test at screening. Exclusion Criteria: - Any clinically significant safety concerns (laboratory, electrocardiogram [EKG], physical examination, other) that, in the opinion of the Investigator, would place the patient at undue risk if the patient were to participate in the study; - Undergoing any current treatment for cancer (radiation therapy, surgery or chemotherapy); - Diabetic with insulin dependence (Patients who have a known insulin dependence for diabetes can be included in the study if the standard of care protocol in place at the clinical site provides for the management of the patient's glucose level sufficiently to allow the PET/CT imaging to be performed. The same glucose management used for the PET/CT imaging should be applied to the SPECT/CT imaging procedures. A waiver will be required to be completed by the clinical site and approved by the sponsor or designee; - Patient weight above the SPECT/CT and PET/CT table weight limit; - Failure to have a non-incisional biopsy definitive diagnosis for NSCLC (or cytology report from a bronchoscope); [a copy of the biopsy/cytology report must be available to the investigator within 28 days of Visit 1]; - Will not agree to use an effective means of contraception for the duration of the study (males and females); - Known hypersensitivity to EC-DG or FDG or similar compounds including any of the inactive ingredients; - Known or suspected pregnancy, lactation or planned pregnancy (females and male partners); - Clinically significant mental illness (to be determined by the Investigator); - Exposure to any investigational agent within 30 days prior to screening visit or participating in an ongoing clinical study (this criteria can be overruled by the Principal Investigator with appropriate documentation of the reason for the exception); - Patient has a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
Canada | Lions Gate Hospital | North Vancouver | British Columbia |
United States | John Hopkins University | Baltimore | Maryland |
United States | Montefiore Medical Center, Department of Nuclear Medicine | Bronx | New York |
United States | Baptist Health South Florida | Coral Gables | Florida |
United States | Decatur Memorial Hospital Department of Radiology | Decatur | Illinois |
United States | Mayo Clinic, Division of Nuclear Medicine | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Cell>Point LLC | Biomedical Services, Camargo Pharmaceutical Services, Numoda, Venn Life Sciences |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety: Through adverse event collection | from 99m Tc-Ec-DG injection through 21 days | Yes | |
Secondary | Efficacy: Comparison of 18F FDG PET/CT image against 99m Tc-EC-DG image | End of study | No | |
Secondary | Efficacy: determine comparability of diagnostic information between SPECT (acs) and SPECT/CT (als) imaging | End of Study | No | |
Secondary | Efficacy: To provide evidence of 99m Tc-Ec-DG in identifying anatomical regions with known Non-small cell lung cancer and in determining extent of disease in these patients as compared to 18F-FDG PET/CT imaging | End of Study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 |